ALS

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

In the Lab Isabella Cueto

When spinal fluid from ALS patients was put into mice, the mice got weak. An unlikely protein could be the culprit

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment

Biotech Adam Feuerstein

Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

Pharmalot Ed Silverman

FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

Biotech Adam Feuerstein

Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments

Biotech Adam Feuerstein

Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval

Biotech Adam Feuerstein

Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome